Navigation Links
Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
Date:6/6/2009

the FDA may not agree with Orexigen's interpretation of efficacy and safety results; earlier clinical trials may not be predictive of future results; Contrave or Empatic may not receive regulatory approval on a timely basis or at all, and the FDA may require Orexigen to complete additional clinical, non-clinical or other requirements prior to the submission or the approval of NDAs for either product candidate; the potential for adverse safety findings relating to Contrave or Empatic to delay or prevent regulatory approval or commercialization, or result in product liability claims; the third parties on whom Orexigen relies to assist with the development programs for Contrave or Empatic, including clinical investigators, contract laboratories, clinical research organizations and manufacturing organizations, may not successfully carry out their contractual duties or obligations or meet expected deadlines, and the quality or accuracy of the data or materials generated by such third parties may be of insufficient quality to include in the Company's regulatory submissions; the ability of Orexigen and its licensors to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
2. Orexigen(R) Therapeutics to Present at Upcoming Meetings
3. Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
4. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
5. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
6. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
7. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
8. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
9. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
10. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
11. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 /PRNewswire/ ... announced today that rare disease expert John C. ... research. Dr. McKew brings more than two decades of ... the National Institutes of Health, Wyeth Research and Genetics ... will lead aTyr,s efforts to expand and translate its ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 ... announced that a team from Iowa State University won ... design contest. Using a Convey HC-2ex, the team’s solution ... 14 times faster than the second place finisher. , ... world embarked upon the month long challenge, using a ...
(Date:10/20/2014)... 20, 2014 , A major ... and the delivery of care has revealed changing trends ... inequalities in the provision of healthcare services across the ... by United European Gastroenterology (UEG), have been announced today ... awareness of the burden of GI disorders across ...
(Date:10/20/2014)... 2014 OncLive® is ... Center at Thomas Jefferson University has joined its ... Strategic Alliance Partnership program, the Sidney Kimmel Cancer ... raise awareness of the Center’s cutting-edge research programs, ... Clinicians and other health care professionals from the ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... China, Aug. 18 /PRNewswire-FirstCall/,-- MicuRx Pharmaceuticals, ... antibiotics, today announced the nomination of,MRX- ... candidate. MRX-I is an,antibacterial molecule targeting ... aureus (MRSA).,Simultaneously, the company expanded its ...
... Drug Target Knowledge Databases ... Related to Nuclear Receptors and Proteases, PARIS, August ... solutions that accelerate life sciences discovery,announced today the release ... include knowledge databases for the important,drug targets Nuclear Receptor ...
... Aug. 18 /Xinhua-PRNewswire-FirstCall/ -- Lotus,Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ... of China,("PRC"), today announced financial results for the quarter and ... Highlights -- Total revenues increased to $19.4 million, up ... 2007 -- Gross profit was $9.7 million, up 76.4% ...
Cached Biology Technology:MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China 2Aureus Pharma Releases New Unified Knowledge Database 2Lotus Pharmaceuticals Announces Second Quarter 2008 Results 2Lotus Pharmaceuticals Announces Second Quarter 2008 Results 3Lotus Pharmaceuticals Announces Second Quarter 2008 Results 4Lotus Pharmaceuticals Announces Second Quarter 2008 Results 5Lotus Pharmaceuticals Announces Second Quarter 2008 Results 6Lotus Pharmaceuticals Announces Second Quarter 2008 Results 7Lotus Pharmaceuticals Announces Second Quarter 2008 Results 8Lotus Pharmaceuticals Announces Second Quarter 2008 Results 9Lotus Pharmaceuticals Announces Second Quarter 2008 Results 10Lotus Pharmaceuticals Announces Second Quarter 2008 Results 11Lotus Pharmaceuticals Announces Second Quarter 2008 Results 12Lotus Pharmaceuticals Announces Second Quarter 2008 Results 13Lotus Pharmaceuticals Announces Second Quarter 2008 Results 14Lotus Pharmaceuticals Announces Second Quarter 2008 Results 15
(Date:10/18/2014)... 2014 Psychological stress and stress-related psychiatric disorders are ... but the molecular mechanisms underlying this relation ... to the development of targeted preventive strategies ... devastating diseases. This work is presented at ... Berlin., Now an international group of researchers ...
(Date:10/18/2014)... In a sample of patients with undiagnosed, suspected genetic ... associated with a higher molecular diagnostic yield than traditional ... JAMA . The study is being released to ... meeting. , Exome sequencing, which sequences the protein­coding region ... genetic material present in a cell or organism), has ...
(Date:10/17/2014)... is available in German . ... sperms every day in order to reproduce? And why are ... topic of the latest issue of the research journal ... evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has compiled ... not unusual for a female to copulate with several males ...
Breaking Biology News(10 mins):Researchers find why depression and aging linked to increased disease risk 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2
... people usually don,t die from a heart attack. But the ... succumb to congestive heart failure, the most common cause of ... hope for achieving what the body can,t do: mending broken ... built a scaffold that supports the growth and integration of ...
... -- A microscopic gene may play a gigantic role when ... to one Kansas State University research team. The team ... Disintegrin and Metalloprotease family, or ADAM family, and its role ... is a good guy or a bad guy in breast ...
... against cancerous tumors, radiation therapy often harms healthy tissue as ... of Tel Aviv University,s Department of Biomedical Engineering is developing ... and minimal damage to surrounding tissue. His innovative ... uses heat to kill the tumor cells but leaves ...
Cached Biology News:A strategy to fix a broken heart 2A strategy to fix a broken heart 3K-State research team investigates mutated gene's role in breast cancer 2A 'magnetic' solution to identify and kill tumors 2
ANTI PIG LDH H4...
... in refrigerators, freezers, or liquid nitrogen. Conveniently sized to ... color coding to project, user, lab, etc. Holes in ... air circulation. Supplied with 10 x 10 (11.6 mm ... dimensions: 13 x 13 x 5.1 cm H (5 ...
Recombinant Rhesus Monkey IFN-Alpha...
RABBIT ANTI AMPHOTERIN...
Biology Products: